Aligos Therapeutics (NASDAQ:ALGS) Releases Quarterly Earnings Results, Beats Estimates By $0.18 EPS

Aligos Therapeutics (NASDAQ:ALGSGet Rating) posted its earnings results on Thursday. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.18, Fidelity Earnings reports. Aligos Therapeutics had a negative return on equity of 68.36% and a negative net margin of 1,547.22%. During the same quarter in the prior year, the firm posted ($0.79) earnings per share.

Aligos Therapeutics Price Performance

NASDAQ ALGS opened at $1.50 on Friday. The stock has a fifty day moving average of $1.35 and a 200-day moving average of $1.83. Aligos Therapeutics has a 52 week low of $1.03 and a 52 week high of $17.97.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on ALGS shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Aligos Therapeutics in a report on Wednesday, June 8th. SVB Leerink cut Aligos Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, May 5th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Aligos Therapeutics presently has an average rating of “Hold” and a consensus price target of $7.00.

Institutional Investors Weigh In On Aligos Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of America Corp DE increased its stake in shares of Aligos Therapeutics by 1.7% in the 1st quarter. Bank of America Corp DE now owns 1,184,258 shares of the company’s stock valued at $2,546,000 after buying an additional 19,958 shares during the period. Mirabella Financial Services LLP acquired a new stake in shares of Aligos Therapeutics in the 1st quarter valued at $88,000. Goldman Sachs Group Inc. increased its stake in shares of Aligos Therapeutics by 343.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 131,162 shares of the company’s stock valued at $282,000 after buying an additional 101,577 shares during the period. PDT Partners LLC acquired a new stake in shares of Aligos Therapeutics in the 1st quarter valued at $57,000. Finally, State Street Corp increased its stake in shares of Aligos Therapeutics by 3.8% in the 1st quarter. State Street Corp now owns 404,756 shares of the company’s stock valued at $870,000 after buying an additional 14,719 shares during the period. 70.21% of the stock is owned by institutional investors and hedge funds.

About Aligos Therapeutics

(Get Rating)

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB.

Recommended Stories

Earnings History for Aligos Therapeutics (NASDAQ:ALGS)

Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.